JP2019534335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534335A5 JP2019534335A5 JP2019546769A JP2019546769A JP2019534335A5 JP 2019534335 A5 JP2019534335 A5 JP 2019534335A5 JP 2019546769 A JP2019546769 A JP 2019546769A JP 2019546769 A JP2019546769 A JP 2019546769A JP 2019534335 A5 JP2019534335 A5 JP 2019534335A5
- Authority
- JP
- Japan
- Prior art keywords
- dry eye
- eye disease
- formulation
- disease according
- treating dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 18
- 238000009472 formulation Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 229960005174 ambroxol Drugs 0.000 claims 7
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims 7
- 150000003839 salts Chemical group 0.000 claims 4
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims 3
- 239000000654 additive Substances 0.000 claims 3
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims 3
- 229920000249 biocompatible polymer Polymers 0.000 claims 3
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 229960001232 anecortave Drugs 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000007975 buffered saline Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 230000003232 mucoadhesive effect Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- -1 trans-4- (2-amino-3,5-dibromophenylamino) cyclohexanol hydrochloride Chemical compound 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421822P | 2016-11-14 | 2016-11-14 | |
| US62/421,822 | 2016-11-14 | ||
| US201762463717P | 2017-02-26 | 2017-02-26 | |
| US62/463,717 | 2017-02-26 | ||
| PCT/US2017/061108 WO2018089797A1 (en) | 2016-11-14 | 2017-11-10 | Formulations for the treatment of ocular surface diseases and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534335A JP2019534335A (ja) | 2019-11-28 |
| JP2019534335A5 true JP2019534335A5 (enExample) | 2020-01-16 |
| JP6871400B2 JP6871400B2 (ja) | 2021-05-12 |
Family
ID=62107036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546769A Active JP6871400B2 (ja) | 2016-11-14 | 2017-11-10 | 眼表面疾患の治療のための製剤および関連方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10265280B2 (enExample) |
| EP (1) | EP3538083B1 (enExample) |
| JP (1) | JP6871400B2 (enExample) |
| KR (1) | KR102116303B1 (enExample) |
| CN (2) | CN109982692A (enExample) |
| AU (1) | AU2017357755B2 (enExample) |
| CA (1) | CA3043327C (enExample) |
| ES (1) | ES2988280T3 (enExample) |
| WO (1) | WO2018089797A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969511A (zh) * | 2018-07-12 | 2018-12-11 | 图桑医疗科技（深圳）有限公司 | 溴已新及其衍生物在治疗和预防眼表疾病上的应用 |
| US11326176B2 (en) | 2019-11-22 | 2022-05-10 | Mozza Foods, Inc. | Recombinant micelle and method of in vivo assembly |
| US12359212B2 (en) | 2019-11-22 | 2025-07-15 | Mozza Foods, Inc. | Recombinant micelle and method of in vivo assembly |
| CN112915090A (zh) * | 2019-12-07 | 2021-06-08 | 王明武 | 用于治疗眼表疾病的一类化合物及其相关制剂和应用方法 |
| AU2023277608A1 (en) * | 2022-05-21 | 2024-11-28 | Neuvision Development Llc | Topical ocular administration of ambroxol for ocular pain |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU574360B2 (en) | 1983-05-13 | 1988-07-07 | Reichert, D. | Antisnoring agent |
| DE3610997A1 (de) | 1986-04-02 | 1987-10-15 | Krewel Werke Gmbh | Ambroxol-nasenspray |
| DE3731528A1 (de) * | 1987-09-18 | 1989-04-13 | Krewel Werke Gmbh | Verwendung von trans-4- ((2-amino-3,5-dibrom-benzyl)-amino) -cyclohexanol zur lokalen behandlung von erkrankungen des auges |
| JPH08509725A (ja) | 1993-04-30 | 1996-10-15 | ザ、プロクター、エンド、ギャンブル、カンパニー | コートされた医薬組成物 |
| US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| IT1303671B1 (it) | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio |
| AU770803B2 (en) | 1998-12-23 | 2004-03-04 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
| DE19933148A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Int | Ambroxolhaltige Lutschtablette |
| US7179849B2 (en) | 1999-12-15 | 2007-02-20 | C. R. Bard, Inc. | Antimicrobial compositions containing colloids of oligodynamic metals |
| CA2373171A1 (en) | 2000-03-07 | 2001-09-13 | Teijin Limited | Stretch plaster |
| US20030216423A1 (en) | 2000-05-24 | 2003-11-20 | Sergio Ulloa | Stable liquid and solid formulations |
| ITRM20010438A1 (it) * | 2001-07-23 | 2003-01-23 | Farmigea Spa | Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco. |
| DE10140320A1 (de) | 2001-08-16 | 2003-03-06 | Udo Zirfas | Potenzfördernder und vitaltonisierender Wirkstoff |
| DE10203104A1 (de) | 2002-01-25 | 2003-08-07 | Boehringer Ingelheim Pharma | Ambroxol für die Behandlung chronischer Schmerzen |
| US20030171391A1 (en) | 2002-01-25 | 2003-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of chronic pain |
| DE10208313A1 (de) | 2002-02-27 | 2003-09-11 | Boehringer Ingelheim Pharma | Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum |
| US20030166732A1 (en) | 2002-02-27 | 2003-09-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| JP2004175749A (ja) * | 2002-11-28 | 2004-06-24 | Senju Pharmaceut Co Ltd | ドライアイおよびドライアイを伴う疾病の治療剤 |
| DE10332487A1 (de) | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen |
| DE10332486A1 (de) | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung akuter Schmerzen |
| DE10332473A1 (de) | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von Epilepsie |
| AU2003904192A0 (en) * | 2003-08-11 | 2003-08-21 | Adelaide Research and Innovaiton Pty Ltd | Method for inhibiting bacterial colonisation |
| KR20050036166A (ko) * | 2003-10-15 | 2005-04-20 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 인두내 염증 치료용 암브록솔 |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| DE102004021992A1 (de) | 2004-05-03 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Topische Zubereitung enthaltend Ambroxol |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| CA2609549A1 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| EP2793872B1 (en) | 2011-12-22 | 2021-03-10 | Centogene IP GmbH | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
| CN102670607A (zh) | 2012-05-28 | 2012-09-19 | 海南卫康制药(潜山)有限公司 | 复方盐酸氨溴索组合物及其制备方法 |
| US20140235554A1 (en) * | 2013-02-12 | 2014-08-21 | Brian Lawrence | Ophthalmic formulation derived from silk protein |
| HU231191B1 (hu) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Izotóp tartalmú morfin molekulák |
| AU2014309251B2 (en) | 2013-08-23 | 2018-05-24 | Parion Sciences, Inc. | Dithiol mucolytic agents |
-
2017
- 2017-11-10 CN CN201780070126.8A patent/CN109982692A/zh active Pending
- 2017-11-10 US US15/809,659 patent/US10265280B2/en active Active
- 2017-11-10 CN CN202210992714.XA patent/CN115607531A/zh active Pending
- 2017-11-10 CA CA3043327A patent/CA3043327C/en active Active
- 2017-11-10 JP JP2019546769A patent/JP6871400B2/ja active Active
- 2017-11-10 ES ES17868628T patent/ES2988280T3/es active Active
- 2017-11-10 KR KR1020197016988A patent/KR102116303B1/ko active Active
- 2017-11-10 AU AU2017357755A patent/AU2017357755B2/en active Active
- 2017-11-10 EP EP17868628.3A patent/EP3538083B1/en active Active
- 2017-11-10 WO PCT/US2017/061108 patent/WO2018089797A1/en not_active Ceased
-
2019
- 2019-03-19 US US16/358,517 patent/US20190209496A1/en not_active Abandoned
-
2020
- 2020-11-02 US US17/087,504 patent/US20210046022A1/en not_active Abandoned
-
2022
- 2022-07-28 US US17/875,871 patent/US20220378723A1/en not_active Abandoned
-
2024
- 2024-05-15 US US18/664,847 patent/US20240374540A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534335A5 (enExample) | ||
| TW200303749A (en) | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride | |
| EP2408453B1 (en) | Ophthalmic formulations of cetirizine and methods of use | |
| JP6871400B2 (ja) | 眼表面疾患の治療のための製剤および関連方法 | |
| BRPI0519186A2 (pt) | forma de dosagem farmacÊutica oral, sachÊ, formulaÇço lÍquida pronta para o uso, processos para a preparaÇço e para a fabricaÇço do granulado modificador de suspensço, mÉtodo de tratamento de doenÇas relacionadas com Ácido gÁstrico no homem, e, uso de uma forma de dosagem farmacÊutica | |
| Calles et al. | Polymers in ophthalmology | |
| Mandal et al. | Developments in emerging topical drug delivery systems for ocular disorders | |
| JP2020531511A5 (enExample) | ||
| JP2018528169A5 (enExample) | ||
| CN110352075A (zh) | 角结膜被覆片和角结膜被覆片的制作方法 | |
| Lyons et al. | Commercial amniotic membrane extract for treatment of corneal ulcers in adult horses | |
| EP2379078A2 (en) | Topical formulations of flap inhibitors for administration to an eye | |
| Sharma et al. | A Mini-review on New Developments in nanocarriers and polymers for ophthalmic drug delivery strategies | |
| JP2014533271A5 (enExample) | ||
| Navratil et al. | Improving outcomes in ophthalmology via sustained drug delivery | |
| JP2018534274A (ja) | 一過性受容体電位カチオンチャネルサブファミリーｍメンバー８（ｔｒｐｍ８）拮抗薬及び使用方法 | |
| US20250108001A1 (en) | Topical ocular administration of ambroxol for ocular pain | |
| WO2013049539A1 (en) | A method of blocking or trapping allergens | |
| Kwon | GEL-FORMING EYE DROPS FOR ENHANCED INTRAOCULAR PRESSURE LOWERING FOR TREATMENT OF GLAUCOMA | |
| CN105214092B (zh) | 重组人白细胞介素-1受体拮抗剂及其组合物及药物用途 | |
| CN112915090A (zh) | 用于治疗眼表疾病的一类化合物及其相关制剂和应用方法 | |
| JPWO2021007578A5 (enExample) | ||
| WO2013049538A1 (en) | Allergen nasal compositions | |
| RU2020111560A (ru) | Офтальмологические фармацевтические композиции | |
| HK1164167A (en) | Topical formulations of flap inhibitors for administration to an eye |